Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.37 |
| ▸ | FLT1 | P17948 | 1/20 | 0.37 |
| ▸ | FLT4 | P35916 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4733642 | 0.85 | AR (0.43) | ALDH1A1ARCYP3A4POLBMAPT | |
| SCHEMBL29439779 | 0.85 | AR (0.43) | ALDH1A1ARCYP3A4POLBMAPT | |
| SCHEMBL1050257 | 0.83 | ALDH1A1 (0.62) | ALDH1A1NPC1KDM4EHPGDMAPT | |
| SCHEMBL5960630 | 0.83 | HTT (0.48) | ALDH1A1NPC1ARKDM4EHPGD | |
| SCHEMBL1402749 | 0.81 | KDM4E (0.49) | ALDH1A1KDM4EHPGDPOLBATM | |
| SCHEMBL1423874 | 0.79 | FLT1 (0.55) | ALDH1A1ABCG2POLBFLT1FLT4 | |
| SCHEMBL3291689 | 0.79 | TSHR (0.50) | ALDH1A1NPC1CYP3A4GAAMAPT | |
| SCHEMBL220681 | 0.79 | NPC1 (0.64) | ALDH1A1NPC1HPGDCYP3A4ABCG2 | |
| SCHEMBL11756782 | 0.79 | ACHE (0.52) | ALDH1A1NPC1KDM4EHPGDCYP3A4 | |
| SCHEMBL22108793 | 0.79 | PLK1 (0.53) | ALDH1A1NPC1HPGDPOLBFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4613749-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USE THEREOF | TransThera Sciences (Nanjing), Inc. (CN) | 2025-09-10 | — | — | EP | disclosed |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-12-19 | — | — | US | disclosed |
| US-12116351-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2024-10-15 | — | — | US | disclosed |
| WO-2024094185-A1 | NLRP3 INFLAMMASOME INHIBITOR AND USE THEREOF | 药捷安康(南京)科技股份有限公司 | 2024-05-10 | — | — | WO | disclosed |
| CN-117986258-A | NLRP3 inflammation corpuscle inhibitor and application thereof | 药捷安康(南京)科技股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-12-01 | — | — | US | disclosed |
| US-11434207-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2022-09-06 | — | — | US | disclosed |
| CN-108863959-B | P2X4 receptor antagonists | 日本化学药品株式会社 | 2021-11-30 | — | — | CN | disclosed |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2020-07-16 | — | — | US | disclosed |
| CN-111333588-A | P2X4 receptor antagonists | 日本化学药品株式会社 | 2020-06-26 | — | — | CN | disclosed |
| US-9969700-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD. (JP) | 2018-05-15 | — | — | US | disclosed |
| EP-2803662-B1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO (JP) | 2017-03-01 | — | — | EP | disclosed |
| US-20160280667-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2016-09-29 | — | — | US | disclosed |
| US-9382236-B2 | P2X4 receptor antagonist | NIPPON CHEMIPHAR CO., LTD (JP) | 2016-07-05 | — | — | US | disclosed |
| US-20140357858-A1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO., LTD (JP) | 2014-12-04 | — | — | US | disclosed |
| EP-2803662-A1 | P2X4 RECEPTOR ANTAGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2014-11-19 | — | — | EP | disclosed |
| US-5358948-A | Psychological, nervous system disorders | GLAXCO GROUP LIMITED (GB) | 1994-10-25 | — | — | US | disclosed |
| CN-1073430-A | Benzanilide derivatives | GLAXO GROUP LTD (GB) | 1993-06-23 | — | — | CN | disclosed |
| WO-1993006084-A1 | BENZANILIDE DERIVATIVES AS 5-HT1D ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 1993-04-01 | — | — | WO | disclosed |
| EP-0533267-A1 | Benzanilide derivatives as 5-HT1D antagonists | GLAXO GROUP LIMITED (GB) | 1993-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380322-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | ALDH1A1 3019/4885NPC1 2397/4885AR 851/4885 |
| US-20240417379-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | ALDH1A1 3045/4885NPC1 2413/4885AR 639/4885 |
| US-12116351-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | ALDH1A1 3019/4885NPC1 2397/4885AR 851/4885 |
| US-20160280667-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | ALDH1A1 3013/4885NPC1 2443/4885AR 850/4885 |
| US-20140357858-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | ALDH1A1 3019/4885NPC1 2397/4885AR 851/4885 |
| US-20200223806-A1 | P2X4 RECEPTOR ANTAGONIST | P2RX7, P2RX1, P2RX2 | ALDH1A1 3019/4885NPC1 2397/4885AR 851/4885 |
| US-11434207-B2 | P2X4 receptor antagonist | P2RX7, P2RX1, P2RX2 | ALDH1A1 3019/4885NPC1 2397/4885AR 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.